Search results
Showing results for sunitinib. No results found for Sunitynib.
The page "Sunitynib" does not exist. You can create a draft and submit it for review or request that a redirect be created, but consider checking the search results below to see whether the topic is already covered.
Sunitinib, sold under the brand name Sutent, is an anti-cancer medication. It is a small-molecule, multi-targeted receptor tyrosine kinase (RTK) inhibitor...36 KB (3,366 words) - 22:16, 29 May 2025- (NSCLC). Sunitinib is an oral drug that inhibits the phosphorylation of all the VEGF receptors, PDGFR-ß, KIT FLT3, CSF1R and GDNF. Sunitinib is used in...41 KB (4,751 words) - 17:22, 11 June 2025
effectiveness of everolimus in carcinoid tumors have not been established. sunitinib (Sutent) is labeled for treatment of progressive, well-differentiated...28 KB (2,471 words) - 18:18, 15 May 2025
randomized study of zanzalintinib in combination with nivolumab versus sunitinib in patients with advanced or metastatic non-clear cell RCC (nccRCC). Sharma...5 KB (188 words) - 12:33, 5 September 2024
approved within the past ten years. These treatments are: Nivolumab Axitinib Sunitinib Cabozantinib Everolimus Lenvatinib Pazopanib Bevacizumab Sorafenib Tivozanib...101 KB (11,017 words) - 23:59, 15 June 2025- shut down in 2003, after developing the pioneering kinase inhibitor drug sunitinib (Sutent). Sugen was founded in 1991 in Redwood City, California, by veteran...8 KB (823 words) - 17:00, 26 September 2024
- cytokine therapy (IL-2, interferon), kinase inhibitors (temsirolimus, sunitinib, sorafenib, pazopanib) and anti-angiogenic therapies (bevacizumab). "Clear...3 KB (333 words) - 03:12, 23 February 2025
multiple-tyrosine-kinase inhibitor sunitinib (marketed as Sutent) can be considered.: 26 and 31 The effectiveness of imatinib and sunitinib depends on the genotype...46 KB (4,782 words) - 13:48, 30 April 2025
inhibitor that is effective both as a senolytic and as therapy for CML. Sunitinib, an inhibitor of the receptors for FGF, PDGF and VEGF is also based on...10 KB (1,179 words) - 18:31, 8 August 2024
trial number NCT02231749 for "Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate...49 KB (4,962 words) - 03:28, 19 June 2025- small molecules that inhibit the tyrosine kinases stimulated by VEGF: sunitinib, sorafenib, axitinib, and pazopanib (some of these therapies target VEGF...14 KB (1,701 words) - 19:59, 29 May 2025
- are also found in several drugs, including atorvastatin, ketorolac, and sunitinib. Pyrroles are used as lightfast red, scarlet, and carmine pigments. Structural...34 KB (3,197 words) - 22:33, 22 May 2025
- removal and is causing symptoms, targeted therapy with everolimus or sunitinib can reduce symptoms and slow progression of the disease. Standard cytotoxic...129 KB (13,579 words) - 21:55, 24 May 2025
MedlinePlus. Clinical trial number NCT01835158 for "Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced...26 KB (2,134 words) - 20:14, 29 May 2025- reaction of esters with hydrazine: An applied example is a synthesis of sunitinib begins by mixing 5-fluoroisatin slowly into hydrazine hydrate. After 4...5 KB (446 words) - 06:56, 16 May 2025
phosphate. It was developed by SUGEN as SU11654, a sister compound to sunitinib, which was later approved for human therapies. Toceranib is a tyrosine...7 KB (368 words) - 19:18, 1 May 2025
stabilizers, amiodarone, interferon alpha, tyrosine kinase inhibitors such as sunitinib Central hypothyroidism Lesions compressing the pituitary (pituitary adenoma...75 KB (7,734 words) - 22:06, 8 May 2025
Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...5 KB (381 words) - 03:24, 27 May 2025
Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...9 KB (1,146 words) - 03:36, 10 March 2024- Masitinib Motesanib Nintedanib Pazopanib Radotinib Quizartinib Ripretinib Sunitinib Sorafenib Toceranib Antibodies: Olaratumab Ramucirumab Tovetumab RET (GFL)...12 KB (983 words) - 21:51, 29 May 2025